Articles tagged with: Smoldering Multiple Myeloma
NewsFlash »
Study Reveals Genetic Differences Between MGUS And Multiple Myeloma – In a recent study, Spanish researchers identified chromosomal abnormalities that were more frequent in patients with active mutiple myeloma than in patients with smoldering myeloma and monoclonal gammopathy of undetermined significance (MGUS), a condition that may later progress to smoldering or active myeloma. The researchers also found that chromosomal abnormalities tend to be more frequent in active myeloma patients than in smoldering myeloma patients, and also more frequent in smoldering myeloma patients than in MGUS patients. For more information, please see the study in Leukemia (abstract).
sCD105 Protein May Be An Indicator For Myeloma Severity – Results of a recent study show that levels of the protein sCD105 circulating in the blood are higher in multiple myeloma patients than in healthy individuals. Higher levels of sCD105 also were associated with more advanced stages of disease. sCD105 is known to play a role in the growth of new blood vessels and may thus contribute to tumor progression in myeloma. Researchers believe these findings warrant further study of sCD105 levels as an indicator for disease activity. For more information, please see the study in the European Journal of Internal Medicine (abstract).
Whole Body MRI Adds Limited Value To Routine Myeloma Remission Testing After Transplantation – A recent study found that the use of whole body magnetic resonance imaging (MRI) to detect persisting or relapsing multiple myeloma post transplant offers little added value compared to current routine laboratory tests. The results of the whole body MRI and routine laboratory tests were in agreement in 79 percent of the patients assessed. For more information, please see the study in European Radiology (abstract).
IMF Myeloma Workshop For Patients And Families – The International Myeloma Foundation (IMF) will be hosting a workshop for multiple myeloma patients and their families on May 19 in Indianapolis, IN. Dr. Rafat Abonour from the Indiana University Bone Marrow and Stem Cell Transplantation Program and nurse Kena Miller from the Roswell Park Cancer Institute in Buffalo, NY, will speak about topics including treatment options, managing side effects, and local clinical trials. For more information or to register, please visit the IMF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News»
Many new and promising research developments occurred in the field of multiple myeloma during 2011. Over the course of the year, The Myeloma Beacon published nearly 100 articles on important myeloma-related studies.
To identify the most important of these studies from 2011, The Myeloma Beacon surveyed leading physicians and researchers in the field. They were asked to name the three peer-reviewed journal articles published in 2011 and the three conference presentations from 2011 that have the most important findings or implications relating to multiple myeloma.
Their selections for the most important journal …
News, Resources»
As The Beacon previously reported, Spanish researchers recently presented clinical trial results showing that active treatment may be beneficial for some smoldering multiple myeloma patients.
Specifically, the results of the study showed that high-risk smoldering multiple myeloma patients who received Revlimid plus dexamethasone followed by Revlimid maintenance had a longer time to disease progression and better overall survival than patients who did not receive treatment (see related Beacon news).
To help Beacon readers put these results into perspective and better understand their implications, The Beacon asked myeloma specialist Dr. Ola Landgren for …
News»
The most recent results of a Spanish Phase 3 clinical trial indicate that Revlimid in combination with dexamethasone delays disease progression in smoldering multiple myeloma patients who have a high risk of developing symptomatic disease.
Specifically, the results showed that high-risk smoldering multiple myeloma patients who received Revlimid plus dexamethasone had a longer time to disease progression and better overall survival than patients who did not receive treatment.
However, the Spanish researchers acknowledged that these results should be confirmed by long-term follow-up data, especially regarding the difference in overall survival.
Dr. Ola …
News»
On the fourth and final day of the American Society of Hematology (ASH) 2011 annual meeting, there was one session in the morning with a number of important myeloma-related presentations.
The key findings of those presentations are summarized in this article.
Treatment Of High-Risk Smoldering Myeloma
Dr. María-Victoria Mateos from the University Hospital in Salamanca, Spain, kicked off the session.
She gave a presentation reviewing a Phase 3 trial she and her colleagues are conducting on the treatment of high-risk smoldering myeloma patients with Revlimid (lenalidomide) and dexamethasone (Decadron) (
News»
This past Sunday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting, and it was a particularly busy day for meeting attendees interested in multiple myeloma.
The Beacon published an update yesterday covering two sets of presentations made at Sunday’s oral session about multiple myeloma. This article covers the other set of presentations, which was about myeloma bone disease, as well as material from an afternoon education session focused on myeloma.
Myeloma Bone Disease
The …
News»
Myeloma researchers and physicians gathered at the 2011 International Myeloma Workshop (IMW) earlier this month to discuss the current understanding of the biology and treatment of multiple myeloma.
Highlights from each day of the workshop were covered in the Beacon’s daily updates from the meeting.
Now that the IMW has ended, however, and there has been some time to digest all that happened, it seems like a good time to ask: What were the key themes and learnings from the conference?
To answer this question, The Beacon went back and reviewed its coverage of the IMW, and …
